Leqvio vs Lisinopril: Head-to-Head Efficacy Comparison

Why Comparing These Two Drugs Requires Context

Inclisiran and lisinopril sit on opposite branches of the cardiometabolic treatment tree. Inclisiran (brand name Leqvio) is a small interfering RNA that silences hepatic production of PCSK9, a protein responsible for degrading LDL receptors on liver cells 1. Fewer PCSK9 molecules mean more LDL receptors survive on hepatocyte surfaces, pulling more LDL cholesterol out of circulation.

Lisinopril, by contrast, blocks angiotensin-converting enzyme. This lowers blood pressure, reduces cardiac afterload, and slows kidney damage in patients with diabetes or chronic kidney disease 2. It has no meaningful effect on LDL cholesterol.

Asking "Is Leqvio better than lisinopril?" is a bit like asking whether insulin is better than metoprolol. They solve different problems. A patient with isolated severe hypercholesterolemia and normal blood pressure needs inclisiran (or another lipid-lowering agent). A patient with hypertension and normal lipids needs lisinopril. Many cardiometabolic patients need both.

The American College of Cardiology and the American Heart Association treat lipid management and blood pressure management as parallel but distinct pillars of atherosclerotic cardiovascular disease (ASCVD) risk reduction 3.

Inclisiran Efficacy: What ORION-10 and ORION-11 Showed

Inclisiran's approval rested on two key Phase III trials. In ORION-10 (N=1,561, all U.S. patients with ASCVD) and ORION-11 (N=1,617, ASCVD or ASCVD risk equivalents across Europe and South Africa), patients already on maximally tolerated statin therapy received inclisiran 284 mg subcutaneously at day 0, day 90, and every six months thereafter, or matching placebo 1.

The results were consistent across both trials. ORION-10 demonstrated a time-averaged placebo-adjusted LDL-C reduction of 51.3% and a day-510 reduction of 52.3% (P<0.001 for both). ORION-11 showed a time-averaged reduction of 49.2% and a day-510 reduction of 49.9% (P<0.001) 1. Injection-site reactions occurred in 4.7% of inclisiran-treated patients in ORION-10, though most were mild and transient.

What makes these numbers clinically significant: patients in both trials were already on statin background therapy. Inclisiran delivered its ~50% LDL-C reduction on top of whatever statins had already accomplished. For a patient on atorvastatin 80 mg with a residual LDL of 100 mg/dL, adding inclisiran could bring that number to approximately 50 mg/dL, well below the 70 mg/dL threshold the ACC/AHA recommends for very high-risk ASCVD patients 3.

The twice-yearly dosing schedule also addresses a persistent problem in lipid management: medication adherence. Statin discontinuation rates exceed 50% at two years according to multiple real-world analyses 4. With inclisiran administered by a healthcare provider in a clinical setting, adherence becomes a scheduling question rather than a daily behavioral one.

Lisinopril Efficacy: Lessons from ALLHAT and Beyond

The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) remains the largest randomized antihypertensive trial ever conducted, enrolling 33,357 participants aged 55 and older with hypertension and at least one additional coronary heart disease risk factor 2.

ALLHAT randomized patients to chlorthalidone, amlodipine, or lisinopril. The primary outcome (fatal coronary heart disease or nonfatal myocardial infarction) showed no significant difference between lisinopril and chlorthalidone (RR 0.99; 95% CI 0.91-1.08) 2. Lisinopril performed comparably on most secondary endpoints with one notable exception: the six-year rate of stroke was higher with lisinopril than with chlorthalidone (RR 1.15; 95% CI 1.02-1.30). This finding has been attributed to slightly less effective blood pressure control in Black participants randomized to the ACE inhibitor arm 2.

Outside ALLHAT, lisinopril has a broad evidence base supporting its use in heart failure with reduced ejection fraction. The ATLAS trial (N=3,164) found that high-dose lisinopril (32.5-35 mg daily) reduced the combined risk of death and hospitalization for heart failure by 12% compared to low-dose lisinopril (2.5-5 mg daily) 5. ACE inhibitors as a class also slow the progression of diabetic nephropathy, a benefit confirmed in the landmark Lewis trial with captopril 6 and extended to the class as a whole by subsequent guidelines from the American Diabetes Association 7.

Lisinopril's side effect profile is well characterized after nearly four decades of clinical use. Dry cough occurs in 5-20% of patients and is the most common reason for discontinuation. Angioedema is rare (0.1-0.7%) but potentially life-threatening, with higher incidence in Black patients 8. Hyperkalemia requires monitoring, particularly when lisinopril is combined with potassium-sparing diuretics or mineralocorticoid receptor antagonists.

Mechanism of Action: Entirely Different Pathways

Understanding why these drugs cannot substitute for each other requires a look at their molecular targets. Inclisiran is a double-stranded small interfering RNA conjugated to triantennary N-acetylgalactosamine (GalNAc), which binds asialoglycoprotein receptors on hepatocytes. Once internalized, the antisense strand enters the RNA-induced silencing complex (RISC) and degrades PCSK9 messenger RNA before the protein can be translated 9. The result: PCSK9 protein levels drop, LDL receptor density on liver cells increases, and circulating LDL-C falls.

Lisinopril competitively inhibits angiotensin-converting enzyme, blocking the conversion of angiotensin I to angiotensin II. This reduces vasoconstriction, aldosterone secretion, and sympathetic nervous system activation 10. Blood pressure drops. Cardiac remodeling slows. Glomerular filtration pressure in the kidneys decreases, protecting the nephron.

These two mechanisms operate in parallel, not in series. A patient can have perfectly controlled blood pressure and dangerously elevated LDL, or vice versa. The drugs do not compete for the same physiological target.

Dosing, Administration, and Practical Considerations

The practical differences between these medications are significant for patient selection. Inclisiran requires a subcutaneous injection of 284 mg at initiation, again at three months, and then every six months. Each injection must be administered by a healthcare professional, which means the patient needs a clinic visit or home health service 11. The drug is stored refrigerated (2-8°C) until use.

Lisinopril is a once-daily oral tablet available in 2.5, 5, 10, 20, 30, and 40 mg strengths. Most patients start at 5-10 mg and titrate upward. The drug is stable at room temperature and widely available at every pharmacy in the United States. Generic lisinopril costs between $4 and $15 per month at most retail pharmacies.

From a cost perspective, inclisiran's wholesale acquisition cost is approximately $3,250 per injection, translating to $6,500 annually after the loading-dose year. Medicare Part B covers inclisiran as a physician-administered drug under the buy-and-bill model, which has improved access for eligible patients. Commercial coverage varies by plan and often requires prior authorization demonstrating statin intolerance or inadequate LDL-C reduction on maximally tolerated oral therapy.

Dr. Christie Ballantyne, chief of cardiology at Baylor College of Medicine and a principal investigator in the ORION program, has noted: "Inclisiran fills a specific gap for patients who cannot reach their LDL goals with statins alone. It is not a replacement for foundational therapies like ACE inhibitors or statins; it is an addition to them."

Cardiovascular Outcomes: The Evidence Gap

One area where the comparison becomes nuanced involves hard cardiovascular outcomes (myocardial infarction, stroke, cardiovascular death). Lisinopril and the ACE inhibitor class have decades of outcomes data. The Heart Outcomes Prevention Evaluation (HOPE) trial demonstrated that ramipril (a related ACE inhibitor) reduced MI, stroke, and cardiovascular death by 22% versus placebo in high-risk patients, independent of blood pressure lowering 12.

Inclisiran does not yet have completed cardiovascular outcomes data. The ORION-4 trial (NCT03705234), a randomized, double-blind, placebo-controlled outcomes study enrolling approximately 15,000 patients with pre-existing ASCVD, is expected to report results in 2026 13. Until ORION-4 reports, clinicians infer outcomes benefit from inclisiran based on the well-established relationship between LDL-C reduction and ASCVD event reduction. A meta-analysis by the Cholesterol Treatment Trialists' Collaboration found that each 1 mmol/L (38.7 mg/dL) reduction in LDL-C reduces major vascular events by approximately 22% 14.

That inference is strong but indirect. Lisinopril's cardiovascular protection, by contrast, has been demonstrated in multiple randomized outcomes trials spanning more than 30 years. This distinction matters for evidence-based decision-making.

Who Gets Which Drug (or Both)

Clinical decision-making between these agents follows a straightforward algorithm based on which risk factors a patient has. The 2018 ACC/AHA cholesterol guideline recommends intensifying LDL-C-lowering therapy for patients with clinical ASCVD whose LDL-C remains at or above 70 mg/dL on maximally tolerated statin therapy 3. Inclisiran is positioned after ezetimibe and PCSK9 monoclonal antibodies (evolocumab, alirocumab) in the treatment cascade, though some clinicians now consider it alongside these options given its convenient dosing.

The 2017 ACC/AHA blood pressure guideline recommends ACE inhibitors (including lisinopril) as first-line therapy for hypertension in most non-Black patients and in all patients with diabetes, chronic kidney disease, or heart failure with reduced ejection fraction 15. Black patients with hypertension and no compelling indication for an ACE inhibitor are generally started on a calcium channel blocker or thiazide diuretic, consistent with ALLHAT findings.

Many patients require both drugs. A 62-year-old with a prior MI, hypertension, type 2 diabetes, and an LDL-C of 85 mg/dL on rosuvastatin 40 mg plus ezetimibe would be a candidate for lisinopril (blood pressure and renal protection) and inclisiran (further LDL-C reduction toward the <55 mg/dL European Society of Cardiology target). These drugs do not interact pharmacokinetically and can be prescribed concurrently without dose adjustment.

Safety Profiles Compared

The side-effect landscapes of these drugs reflect their distinct mechanisms. Inclisiran's most reported adverse event in ORION-10 and ORION-11 was injection-site reaction (4.7% vs. 0.5% placebo), consisting of erythema, pain, or rash at the injection site. Bronchitis, urinary tract infection, and back pain occurred at similar rates in treatment and placebo groups. No significant hepatotoxicity signals emerged 1.

Lisinopril carries a well-documented side effect profile. The ACC/AHA hypertension guideline notes that ACE inhibitor-associated cough occurs in up to 15% of patients and is more common in women and Asian populations 15. Angioedema, while rare, requires immediate discontinuation. Hyperkalemia risk increases when lisinopril is co-prescribed with potassium supplements, potassium-sparing diuretics, or in patients with estimated GFR below 30 mL/min/1.73m². Both drugs are contraindicated in pregnancy.

As the 2018 ACC/AHA cholesterol guideline states: "The net benefit of LDL-C lowering with non-statin therapies should be weighed against the potential for adverse effects, drug-drug interactions, and patient preferences" 3.

The Bottom Line for Patients

Choosing between inclisiran and lisinopril is rarely the actual clinical question. The real question is which combination of therapies best addresses a given patient's full cardiometabolic risk profile. A patient with elevated LDL-C and normal blood pressure does not need lisinopril for lipid control. A patient with hypertension and normal cholesterol does not need inclisiran for blood pressure management.

For the subset of patients who have both elevated LDL-C despite maximally tolerated statin therapy and hypertension or heart failure, the answer is typically both drugs, prescribed for their respective indications. Clinicians should verify LDL-C targets per the 2018 ACC/AHA guideline (<70 mg/dL for very high-risk ASCVD, with a <55 mg/dL option per ESC guidelines) and blood pressure targets per the 2017 ACC/AHA guideline (<130/80 mmHg for most adults with hypertension) before adding either agent 3 15.

Patients currently on lisinopril whose LDL-C remains above goal should discuss adding inclisiran with their prescriber at the next scheduled lipid panel review, not replacing lisinopril with it.